Document:

Amendment #2 to Amended and Restated Development, License, and Supply Agreement

 Exhibit 10.9 
 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “***”. A COMPLETE VERSION OF THE EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

AMENDMENT #2 
 TO AMENDED AND RESTATED DEVELOPMENT, 
 LICENSE AND SUPPLY
AGREEMENT 
 This Amendment # 2 effective as of the last date on the signature page hereof (“Effective Date”),
by and between CIMA LABS INC. (“CIMA”) and Alamo Pharmaceuticals, LLC (“ALAMO”) amends and supplements that certain Amended and Restated Development, License and Supply Agreement between CIMA and ALAMO dated August 22, 2005,
as amended by that Amendment #1 to Amended And Restated Development, License and Supply Agreement effective October 19, 2005 (collectively, the “Agreement”). 
 WHEREAS, CIMA is currently developing a 12.5 mg orally disintegrating tablet dose of the Product for ALAMO, using CIMA’s DuraSolv® technology, under the terms of the Agreement; 

WHEREAS, ALAMO and CIMA agree that such 12.5 mg orally disintegrating tablet dose should be added to the definition of the Agreement for
purposes of commercialization; 
 NOW, THEREFORE, the parties hereby agree to amend the Agreement as follows: 

 

	 	1.	Except as expressly defined herein, all capitalized terms shall have the meanings set forth in the Agreement. 

 

	 	2.	The definition of “Product” in Section 1 of the Agreement shall be deleted in its entirety and replaced with the following: 

“Product” shall mean a pharmaceutical product containing (i) 12.5 mg, 25 mg, 50 mg, or 100 mg of API formulated in
DuraSolv® technology for the United States; and (ii) 25 mg, 50 mg, or 100 mg, of API formulated in OraSolv® technology for Europe; provided that the 50 mg dose is subject to successful validation pursuant to a mutually agreed upon
development agreement. The Product definition shall be expanded to include a 12.5 mg DuraSolv® dose for Europe provided the Parties reasonably agree upon the terms and conditions of a development agreement outlining the activities and fees
associated with such dose and the Parties reasonably agree to the royalty rate and price for the such product for Europe. 

	 	3.	Section 5.1(c) shall be deleted in its entirety and replaced with the following: 

“Purchase order quantities shall be equivalent to the validated full batch size of the Product, Product samples, or Product placebos.
The delivery quantity of tablets for trade shall not exceed a total of       ***       in any     ***           ,
unless otherwise agreed to by the Parties. Each purchase order shall be placed in accordance with the dosage combinations and full batch split ratios set forth in the final approved validation summary report and any of its approved amendments.

 Alamo will compensate CIMA at the mutually agreed amount for validation activities as set forth in Amendment 1 Schedule B-1
under Stage V. 
  

	 	4.	Schedule B-1 added to the Agreement by Amendment #1 effective as of October 19, 2005 shall be amended (for purposes of clarification) by adding the phrase “at
*** months” to the phrase “***” in the section entitled “***”. 

  

	 	5.	Schedule B-1 added to the Agreement by Amendment #1 effective as of October 19, 2005 shall be amended by replacing “$***” with “$***” and by
replacing the first two paragraphs regarding *** with the following: 

 “*** 

 

					
	 ***
	  	***	  	***
	 ***
	  	***	  	***
	 ***
	  	***	  	***
	 ***
	  	***	  	***
	 ***
	  	***	  	***

 *** 
 *** 
 *** 
 ***.” 
  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

	 	6.	Schedule B-2 attached to this Amendment #2 shall be incorporated into the Agreement in its entirety and included for all purposes as if it formed part of Schedule B.

  

	 	7.	Schedule F of the Agreement is hereby replaced by Schedule F attached to this Amendment #2. 

 

	 	8.	Unless otherwise set forth in this Amendment #2, all references to Sections or Appendices refer to Sections or Appendices of the Agreement. 

 

	 	9.	In the event of any conflict between this Amendment #2 and the Agreement, the terms of this Amendment #2 shall control. 

 

	 	10.	All other terms and conditions of the Agreement shall remain in full force and effect. 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed in two
originals by their duly authorized representatives. 
  

									
	CIMA LABS INC.	 		 	AZUR PHARMACEUTICALS, LLC,
a subsidiary of Avanir Acquisition Corp., a subsidiary of Avanir Pharmaceuticals
					
	BY:	 	 /s/ Raj K. Khankari
	 		 	BY:	 	 /s/ Randall Kaye

									
					
	NAME:	 	 Raj K. Khankari
	 		 	NAME:	 	 Randall Kaye

					
	TITLE:	 	 Gen. Mgr. + Vice President Global Drug Delivery Tech.
	 		 	TITLE:	 	 Chief Medical Officer

					
	DATE:	 	 April 6, 2007
	 		 	DATE:	 	 4/10/2007

 Amended and Restated Development, License and Supply Agreement 

Schedule B-2 
 ***

  

	1.	*** 

  

	2.	*** 

  

	3.	*** 

 *** 

 

	1.	*** 

  

	 	a.	*** 

  

	 	b.	*** 

  

	 	c.	*** 

 *** 

*** 
 *** 

*** 
  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

 Amended and Restated Development, License and Supply Agreement  

Schedule F 

Cost of Goods 
 Pursuant to Sections 5.1, 5.3 and 5.6, Alamo shall pay to CIMA for Product the amounts indicated on the following schedule in respect of CIMA’ s manufacturing obligations hereunder. 

TRADE and SAMPLES (cost per tablet) 
  

							
	 Potency
	  	Total Cost (1) (2)	 	  	 Packaging

	 12.5 mg
	  	$	***	  	  	100 count bottles
	 25 mg
	  	$	***	  	  	(3)
	 50 mg
	  	$	***	  	  	(3)
	 100 mg
	  	$	***	  	  	(3)

  

	(1)	The cost per tablet does not include the cost of API. The parties acknowledge and agree that these prices are based upon one or two dose splits per batch. If Alamo
would like CIMA to validate dose splits of more than two per batch, the parties will mutually agree upon an appropriate increase in these prices. 

	(2)	Per tablet costs will be adjusted annually each January 1st, commencing on January 1, 2007, but increases shall not exceed the PPI (Pharmaceutical) increase
for the prior year. 

	(3)	Product using the OraSolv® technology packaged in blisters. Product using DuraSolv® technology packaged in 100 count bottles. 

PLACEBOS (cost per tablet) 
  

							
	 Placebo type
	  	Total Cost (1)	 	  	 Packaging

	 12.5 mg
	  	$	***	  	  	100 count bottles
	 25 mg
	  	$	***	  	  	(2)
	 50 mg
	  	$	***	  	  	(2)
	 100 mg
	  	$	***	  	  	(2)

  

	(1)	The parties acknowledge and agree that these prices are based upon one or two dose splits per batch. If Alamo would like CIMA to validate dose splits of more than two
per batch, the parties will mutually agree upon an appropriate increase in these prices. 

	(2)	Product using the OraSolv® technology packaged in blisters. Product using DuraSolv® technology packaged in 100 count bottles. 

 

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.Amendment #3 to Amended and Restated Development, License, and Supply Agreement

 Exhibit 10.10 
 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “***”. A COMPLETE VERSION OF THE EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

AMENDMENT#3 
 TO AMENDED AND RESTATED DEVELOPMENT, 
 LICENSE AND SUPPLY
AGREEMENT 
 This Amendment # 3 effective as of the 1st day of January 2008 (“Effective Date”), by and between
CIMA LABS INC., a Delaware corporation (“CIMA”), and Azur Pharma International III Limited, a Bermuda corporation (“AZUR”), as assignee of Alamo Pharmaceuticals, LLC, amends and supplements that certain Amended and Restated
Development, License and Supply Agreement between CIMA and AZUR dated August 22, 2005, as amended by that Amendment #1 to Amended And Restated Development, License and Supply Agreement effective October 19, 2005 and that Amendment #2 to
Amended and Restated Development, License and Supply Agreement effective April 10, 2007 (“Amendment #2) (collectively, the “Agreement”). 
 WHEREAS, AZUR has determined that it would like to seek approval in Europe of dosage forms of the API formulated in the DuraSolv technology in addition to the OraSolv technology, with the intention that
the DuraSolv formulations will replace the OraSolv formulations upon regulatory approval; 
 WHEREAS, AZUR would like CIMA to
conduct certain activities in connection with the validation of three dosage forms of the API formulated in DuraSolv in blisters and bottles for Europe and CIMA is willing to perform such work, in accordance with the terms and conditions set
forth herein; 
 NOW, THEREFORE, the parties hereby agree to amend the Agreement as follows: 

 

	 	1.	Except as expressly defined herein, all capitalized terms shall have the meanings set forth in the Agreement. 

 

	 	2.	Clause (ii) in the definition of “Product” in Section 1 of the Agreement shall be deleted in its entirety and replaced with the following:

 “(ii) 12.5 mg, 25 mg or 100 mg, of API formulated in OraSolv® or DuraSolv® technology for Europe
subject to successful validation in accordance with this Agreement; provided that upon applicable regulatory approval, the DuraSolv® formulation will replace the corresponding OraSolv® formulation” 

 

	 	3.	 Schedule B-2 attached to this Amendment #3 shall replace Exhibit B-2 attached to this Amendment #3. The parties shall in good faith mutually agree in
writing upon any additional work, e.g., artwork for the European bottles and blisters, necessary to launch 

  
 EXECUTION COPY

	 	 
the Product, and compensation for such work. 

  

	 	4.	Schedule F shall be amended by adding the following sentence: “25mg and 100mg product for Europe will be packaged in both 100 count bottles and six-count blisters.
12.5mg product for Europe will be packaged in 100 count bottles only.” 

  

	 	5.	Unless otherwise set forth in this Amendment #3, all references to Sections or Appendices refer to Sections or Appendices of the Agreement. 

 

	 	6.	In the event of any conflict between this Amendment #3 and the Agreement, the terms of this Amendment #3 shall control. 

 

	 	7.	All other terms and conditions of the Agreement shall remain in full force and effect. 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed in two originals by their duly authorized representatives. 

 

									
	CIMA LABS INC.	 		 	AZUR PHARMA INTERNATIONAL III LIMITED
					
	By:	 	 /s/ R.K. Khankari
	 		 	By:	 	 /s/ JP Furey

									
					
	Name:	 	 R.K. Khankari
	 		 	Name:	 	 JP Furey

					
	Title:	 	 General Manager, CIMA VP, Worldwide Drug Delivery Technologies
	 		 	Title:	 	 Vice President

					
	Date:	 	 March 11, 2008
	 		 	Date:	 	 April 2, 2008

  
 EXECUTION COPY

 Amended and Restated Development, License and Supply Agreement 

Schedule B-2 
 ***

 *** 
 Development Activities, Duration and Costs Summary 
  

									
		  	***	  		  	***	  	 ***

					
	 ***
	  		  	***	  		  	 ***

 *** 
  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

 *** 

	1.	*** 

  

	2.	*** 

  

	3.	*** 

  

	4.	*** 

  

	5.	*** 

  

	6.	*** 

  

	7.	*** 

  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

  
 EXECUTION COPY

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}]]